Succinate prodrug - Imbria Pharmaceuticals
Alternative Names: IMB-203Latest Information Update: 26 Mar 2022
At a glance
- Originator Imbria Pharmaceuticals
- Class Succinates
- Mechanism of Action Mitochondrial oxidative phosphorylation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Mitochondrial disorders; Propionic acidaemia